URGN PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

URGN ▲ +1.33% at T+20d

LONG call ✓ call won +1.33% · α vs SPY -1.45% · entry $26.25 → $26.60

Next anchor: T+60d in 7w

Last close $27.25 (close Jun 8) · +3.81% from $26.25 entry

Entry anchored
May 6, 07:05 AM ET
via Databento tick

T+1d

+1.30%

call +1.30% · α +1.63%

$26.59

settled 5w ago

T+5d

+13.52%

call +13.52% · α +12.39%

$29.80

settled 28d ago

T+20d

+1.33%

call +1.33% · α -1.45%

$26.60

settled 6d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

UroGen reported Q1 2026 total revenue of $51.0M (+152% YoY), driven by ZUSDURI's launch ($29.2M, +109% QoQ) and JELMYTO growth ($21.7M, +7% YoY). Net loss narrowed to $23.6M ($0.47/share) from $43.8M ($0.92/share) a year ago, beating the consensus EPS estimate of -$0.48. The company maintained JELMYTO revenue guidance of $97-101M and operating expense guidance of $240-250M for 2026.

Key Financial Metrics

Guidance

$97M-$101M (JELMYTO only)

maintained

Gross Margin

91.9%

Actionable Insight

ZUSDURI's accelerating launch trajectory (109% QoQ) validates the blockbuster thesis and drives the beat. Watch for continued site-of-care expansion and repeat prescriber growth in Q2. The maintained JELMYTO guidance and controlled OpEx provide a clean setup. Key catalysts ahead: UGN-103 NDA submission (H2 2026) and AUA KOL panel on May 17.

Key Facts

Total revenue $51.0M vs $20.3M YoY (+152%), beating consensus $44.8M
ZUSDURI net product revenue $29.2M in first full quarter of launch (109% QoQ growth)
JELMYTO revenue $21.7M (+7% YoY), in line with full-year guidance of $97-101M
Net loss $23.6M ($0.47/share) vs consensus -$0.48 — a beat
Cash and equivalents $140.3M; $200M debt facility from Pharmakon refinanced existing debt
UGN-103 NDA submission on track for H2 2026; UGN-104 Phase 3 enrollment expected by end of 2026
972 activated sites of care, 256 unique ZUSDURI prescribers as of March 31, 2026

Financial Impact

Revenue beat consensus by $6.2M (13.8%); EPS beat consensus by $0.01 (2.1%)

revenuenet losscash position

Risk Factors

ZUSDURI adoption may decelerate as early adopter pool saturates
SG&A expenses rose 47% YoY to $51.5M, outpacing revenue growth rate
Shareholders' deficit of $124.3M; reliance on debt financing for operations
UGN-103/104 clinical and regulatory timelines could slip

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3288758

7 reports for URGN

T+1T+5T+20T+60

75% Hit rate 3 of 4 directional calls best @ T+60▲ +54.89%Mar 2, 2026

Filters

Reports for URGN — sortable, filterable
	Type				Now
Jun 2, 2026 7d ago	8-K NEUTRAL ★ 5/10	$26.54 $26.60	▲ +0.23%	▲ +0.92%	$27.25 (+2.68%)
May 16, 2026 24d ago	ANALYST-UPGRADE BULLISH ★ 1/10	$14.34 $13.24	▼ −7.67%	▼ −6.83%	$27.25 (+90.03%)
May 6, 2026 4w ago	Press Release BULLISH ★ 7/10	$26.25 $26.59	▲ +1.30%	▲ +1.63%	$27.25 (+3.81%)
Apr 29, 2026 5w ago	Press Release BEARISH ★ 7/10	$23.34 $23.83	▼ −2.10%	▼ −1.08%	$27.25 (−16.75%)
Apr 16, 2026 7w ago	ANALYST-UPGRADE BULLISH ★ 5/10	$21.39 $22.54	▲ +5.38%	▲ +4.16%	$27.25 (+27.40%)
Mar 2, 2026 14w ago	Press Release MIXED ★ 6/10	$19.02 $18.82	▼ −1.05%	▼ −0.14%	$27.25 (+43.27%)
Mar 2, 2026 14w ago	Press Release BULLISH ★ 7/10	$19.02 $18.82	▼ −1.05%	▼ −0.14%	$27.25 (+43.27%)

US Market Status

Market Closed — Opens in 7h 1m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access